Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Vertex, Inc. (NASDAQ: VERX) has announced plans to release its first quarter 2025 financial results on Wednesday, May 7, 2025 ...

Fox News senior national correspondent Aishah Hasnie reports on former President Joe Biden's first public remarks since ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Learn more about whether SoundHound AI, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Morgan Stanley lowered the firm’s price target on Vertex (VERX) to $55 from $60 and keeps an Overweight rating on the shares. The firm is ...

Google Cloud's updated its Vertex AI platform to support AI agents with including the Agent Development Kit, the Agent2Agent ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

In a report released today, Chris Quintero from Morgan Stanley maintained a Buy rating on Vertex (VERX – Research Report), with a price target ...

Google is adding a new open source framework for building agents to its AI and machine learning platform Vertex AI, along ...